🇺🇸 FDA
Pipeline program

TL-895, TL-895

MS200662_0001

Phase 2 small_molecule active

Quick answer

TL-895, TL-895 for B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials